13 / 38
1
st
L IO+CT: Does PDL1 worth?
(63% cross-over to anti-PD(L)-1 )
HR: 0.59
(0.34–1.05)
P
= 0.03
Langer – Lancet Oncol 2016 * Borghaei – ESMO 2017 * Langer – WCLC 2017 * Reck – ESMO IO 2017
Ph.II Pem. Carbo.
+/- PEMBROLIZUMAB.
All comers
KEYNOTE 021
Ph.III Pacli. Carbo. Bev.
+/- ATEZOLIZUMAB.
All comers
IMPOWER 150
Press release – 16
th
Jan 2018
Ph. III KEYNOTE 189
Positive for PFS and OS